C

Gilead Sciences, Inc. GILD

$166.69 -$2.29-1.36% NASDAQ
Recommendation
Dividend Power Score
Day's Range
$164.80$169.16
Latest Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
My Lists My Alerts
Access our Premium Ratings
Get Access

GILD Rating

Reward
Risk

GILD Rating Factors

Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index

GILD Company Overview

Gilead Sciences, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines for life-threatening diseases. The company primarily operates in the biotechnology and pharmaceutical industries, with major therapeutic areas including HIV/AIDS, viral hepatitis, oncology, and inflammatory diseases. Gilead generates most of its revenue from antiviral therapies, particularly HIV treatments, while oncology has become an increasingly important growth area following recent acquisitions and product launches. Its portfolio includes therapies marketed under brands such as Biktarvy, Descovy, Genvoya, Trodelvy, Yescarta, and Veklury.

Gilead was founded in 1987 by Michael L. Riordan and evolved from a small biotechnology research company into one of the largest global antiviral drug developers. The company expanded significantly through internal drug development and acquisitions, including the purchases of Pharmasset in 2011, which strengthened its hepatitis C franchise, and Immunomedics in 2020, which expanded its oncology portfolio. Gilead is widely recognized for its leadership in HIV therapeutics, supported by extensive clinical research capabilities, long-term physician relationships, and a large global commercial infrastructure.

Data compiled by narrative technology. May contain errors.
Sector

GILD Income Statement

Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)

GILD Balance Sheet

Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)

GILD Cash Flow

Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)

GILD Price History

Loading...
52-Week Range83% of range
Current
$166.69
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return

GILD Valuation

Market Cap
Market Cap Rank
#105
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)

GILD Dividends and Shares

Shares Outstanding
Dividend Per Share (Most Recent)
Dividend Per Share (TTM)

GILD Corporate Info

Phone Number
650 574 3000
Address
333 Lakeside Drive
Foster City, CA 94404
Country
Year Founded

GILD Filings

Filing Date
Friday, October 30, 2026
Period Date
Wednesday, September 30, 2026
Next Filing
Week of Feb 22 and 26 (est)

GILD Headlines

11/17/2026 - Simply Wall St
11/17/2026 - Zacks Investment Research